{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T20:02:40Z","timestamp":1785787360109,"version":"3.56.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T00:00:00Z","timestamp":1609718400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T00:00:00Z","timestamp":1609718400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI143567-01"],"award-info":[{"award-number":["AI143567-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Virus neutralization by antibodies is an important prognostic factor in many viral diseases. To easily and rapidly measure titers of neutralizing antibodies in serum or plasma, we developed pseudovirion particles composed of the spike glycoprotein of SARS-CoV-2 incorporated onto murine leukemia virus capsids and a modified minimal murine leukemia virus genome encoding firefly luciferase. This assay design is intended for use in laboratories with biocontainment level 2 and therefore circumvents the need for the biocontainment level 3 that would be required for replication-competent SARS-CoV-2 virus. To validate the pseudovirion assay, we set up comparisons with other available antibody tests including those from Abbott, Euroimmun and Siemens, using archived, known samples.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      11 out of 12 SARS-CoV-2-infected patient serum samples showed neutralizing activity against SARS-CoV-2-spike pseudotyped MLV viruses, with neutralizing titers-50 (NT\n                      <jats:sub>50<\/jats:sub>\n                      ) that ranged from 1:25 to 1:1,417. Five historical samples from patients hospitalized for severe influenza infection in 2016 tested negative in the neutralization assay (NT\n                      <jats:sub>50<\/jats:sub>\n                      \u2009&lt;\u200925). Three serum samples with high neutralizing activity against SARS-CoV-2\/MLV pseudoviruses showed no detectable neutralizing activity (NT\n                      <jats:sub>50<\/jats:sub>\n                      \u2009&lt;\u200925) against SARS-CoV-1\/MLV pseudovirions. We also compared the semiquantitative Siemens SARS-CoV-2 IgG test, which measures binding of IgG to recombinantly expressed receptor binding domain of SARS-CoV-2 spike glycoprotein with the neutralization titers obtained in the pseudovirion assay and the results show high concordance between the two tests (R\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20090.9344).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>SARS-CoV-2 spike\/MLV pseudovirions provide a practical means of assessing neutralizing activity of antibodies in serum or plasma from infected patients under laboratory conditions consistent with biocontainment level 2. This assay offers promise also in evaluating immunogenicity of spike glycoprotein-based candidate vaccines in the near future.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12985-020-01472-1","type":"journal-article","created":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T11:06:37Z","timestamp":1609758397000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Neutralization assay with SARS-CoV-1 and SARS-CoV-2 spike pseudotyped murine leukemia virions"],"prefix":"10.1186","volume":"18","author":[{"given":"Yue","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin T.","family":"Larragoite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth S. C. P.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Lama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Cisneros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio C.","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Slev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Rychert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily A.","family":"Innis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayte","family":"Coiras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew T.","family":"Rondina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam M.","family":"Spivak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5318-2982","authenticated-orcid":false,"given":"Vicente","family":"Planelles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,4]]},"reference":[{"key":"1472_CR1","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1038\/s41467-020-15562-9","volume":"11","author":"X Ou","year":"2020","unstructured":"Ou X, Liu Y, Lei X, Li P, Mi D, Ren L, Guo L, Guo R, Chen T, Hu J, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020;11:1620.","journal-title":"Nat Commun"},{"key":"1472_CR2","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","volume":"181","author":"AC Walls","year":"2020","unstructured":"Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;181:281-92 e286.","journal-title":"Cell"},{"key":"1472_CR3","doi-asserted-by":"crossref","unstructured":"Zhang L, Jackson CB, Mou H, Ojha A, Rangarajan ES, Izard T, Farzan M, Choe H. The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity. bioRxiv. 2020.","DOI":"10.1101\/2020.06.12.148726"},{"key":"1472_CR4","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1128\/JVI.70.4.2581-2585.1996","volume":"70","author":"RK Akkina","year":"1996","unstructured":"Akkina RK, Walton RM, Chen ML, Li QX, Planelles V, Chen IS. High-efficiency gene transfer into CD34+ cells with a human immunodeficiency virus type 1-based retroviral vector pseudotyped with vesicular stomatitis virus envelope glycoprotein G. J Virol. 1996;70:2581\u20135.","journal-title":"J Virol"},{"key":"1472_CR5","doi-asserted-by":"publisher","first-page":"5883","DOI":"10.1128\/JVI.69.9.5883-5889.1995","volume":"69","author":"V Planelles","year":"1995","unstructured":"Planelles V, Bachelerie F, Jowett JB, Haislip A, Xie Y, Banooni P, Masuda T, Chen IS. Fate of the human immunodeficiency virus type 1 provirus in infected cells: a role for vpr. J Virol. 1995;69:5883\u20139.","journal-title":"J Virol"},{"key":"1472_CR6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2174\/1566523216666160119093948","volume":"16","author":"I Steffen","year":"2016","unstructured":"Steffen I, Simmons G. Pseudotyping viral vectors with emerging virus envelope proteins. Curr Gene Ther. 2016;16:47\u201355.","journal-title":"Curr Gene Ther"},{"key":"1472_CR7","doi-asserted-by":"publisher","first-page":"8801","DOI":"10.1128\/JVI.77.16.8801-8811.2003","volume":"77","author":"BJ Bosch","year":"2003","unstructured":"Bosch BJ, van der Zee R, de Haan CA, Rottier PJ. The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J Virol. 2003;77:8801\u201311.","journal-title":"J Virol"},{"key":"1472_CR8","doi-asserted-by":"publisher","first-page":"5110","DOI":"10.1128\/JVI.66.8.5110-5113.1992","volume":"66","author":"NR Landau","year":"1992","unstructured":"Landau NR, Littman DR. Packaging system for rapid production of murine leukemia virus vectors with variable tropism. J Virol. 1992;66:5110\u20133.","journal-title":"J Virol"},{"key":"1472_CR9","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood-2008-07-168393","volume":"113","author":"A Bosque","year":"2009","unstructured":"Bosque A, Planelles V. Induction of HIV-1 latency and reactivation in primary memory CD4+ T cells. Blood. 2009;113:58\u201365.","journal-title":"Blood"},{"key":"1472_CR10","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1089\/aid.1991.7.889","volume":"7","author":"V Planelles","year":"1991","unstructured":"Planelles V, Haigwood NL, Marthas ML, Mann KA, Scandella C, Lidster WD, Shuster JR, Van Kuyk R, Marx PA, Gardner MB, et al. Functional and immunological characterization of SIV envelope glycoprotein produced in genetically engineered mammalian cells. AIDS Res Hum Retrovir. 1991;7:889\u201398.","journal-title":"AIDS Res Hum Retrovir"},{"key":"1472_CR11","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/s41423-020-0458-z","volume":"17","author":"C Yi","year":"2020","unstructured":"Yi C, Sun X, Ye J, Ding L, Liu M, Yang Z, Lu X, Zhang Y, Ma L, Gu W, et al. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies. Cell Mol Immunol. 2020;17:621\u201330.","journal-title":"Cell Mol Immunol"},{"key":"1472_CR12","doi-asserted-by":"crossref","unstructured":"Lv H, Wu NC, Tsang OT, Yuan M, Perera R, Leung WS, So RTY, Chan JMC, Yip GK, Chik TSH, et al. Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections. bioRxiv. 2020.","DOI":"10.1101\/2020.03.15.993097"},{"key":"1472_CR13","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41586-020-2380-z","volume":"584","author":"B Ju","year":"2020","unstructured":"Ju B, Zhang Q, Ge J, Wang R, Sun J, Ge X, Yu J, Shan S, Zhou B, Song S, et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. 2020;584:115\u20139.","journal-title":"Nature."},{"key":"1472_CR14","doi-asserted-by":"publisher","first-page":"104613","DOI":"10.1016\/j.jcv.2020.104613","volume":"132","author":"MA Trabaud","year":"2020","unstructured":"Trabaud MA, Icard V, Milon MP, Bal A, Lina B, Escuret V. Comparison of eight commercial, high-throughput, automated or ELISA assays detecting SARS-CoV-2 IgG or total antibody. J Clin Virol. 2020;132:104613.","journal-title":"J Clin Virol"},{"key":"1472_CR15","doi-asserted-by":"publisher","first-page":"606393","DOI":"10.3389\/fmolb.2020.606393","volume":"7","author":"S Kotta","year":"2020","unstructured":"Kotta S, Aldawsari HM, Badr-Eldin SM, Alhakamy NA, Md S, Nair AB, Deb PK. Combating the Pandemic COVID-19: Clinical Trials, Therapies and Perspectives. Front Mol Biosci. 2020;7:606393.","journal-title":"Front Mol Biosci"},{"key":"1472_CR16","doi-asserted-by":"publisher","first-page":"9490","DOI":"10.1073\/pnas.2004168117","volume":"117","author":"K Duan","year":"2020","unstructured":"Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, Zhou M, Chen L, Meng S, Hu Y, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci USA. 2020;117:9490\u20136.","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-020-01472-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12985-020-01472-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-020-01472-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T11:10:14Z","timestamp":1609758614000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-020-01472-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,4]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1472"],"URL":"https:\/\/doi.org\/10.1186\/s12985-020-01472-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.07.17.207563","asserted-by":"object"}]},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,4]]},"assertion":[{"value":"15 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"We used de-identified, archived serum samples throughout the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have agreed to publication of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1"}}